Sartorius (0NIR) Share Price & Analysis
0NIR Stock Chart & Stats
- Day’s Range
- EUR 290.10 - EUR 297.80
- 52-Week Range
- EUR 198.75 - EUR 299.05
- Previous Close
- EUR 298.50
- Volume
- N/A
- Average Volume (3M)
- 36.21K
- Market Cap
- EUR 18.00B
- Enterprise Value
- EUR 22.80B
- Total Cash (Recent Filing)
- EUR 230.70M
- Total Debt (Recent Filing)
- EUR 3.91B
- Price to Earnings (P/E)
- 72.5
- Beta
- 1.46
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 1.51
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.26%
Bulls Say, Bears Say
Bulls Say
Recurring Bioprocess Revenue
The mix of replenishable single-use and filtration products can create repeat purchasing linked to customers’ production volumes. This recurring element gives Sartorius a more durable revenue base than a business dependent only on occasional equipment sales and supports customer retention over multiple production cycles.
Improving Profitability And Cash Flow
Recovered operating profitability and stronger free cash flow indicate that Sartorius is rebuilding earnings quality after the 2024 weakness. Positive and improving cash generation supports debt service, ongoing research and development, and investment in the company’s long-term bioprocess platform.
Biologics Industry Positioning
Sartorius is positioned in a specialized life-science market through tools used in biologic development and manufacturing. Its exposure to regulated pharmaceutical, biotech, and research workflows can support durable customer relationships because these processes require validated equipment, consumables, and services.
Bears Say
Modest Revenue Growth
Low-single-digit revenue growth shows that the recovery in demand has not yet translated into a strong expansion of the top line. Remaining below the 2022 peak suggests customer investment cycles and product mix have not fully normalized, limiting near-term operating leverage and growth visibility.
Elevated Leverage
Debt remains high relative to equity despite improving from 2023, leaving Sartorius with less financial flexibility if growth slows or margins compress. Elevated leverage can constrain capital allocation, increase the importance of consistent cash generation, and reduce room for sizable strategic investment.
Weak Cash Conversion
Although free cash flow is positive and improving, its level remains well below reported net income. This indicates that working-capital demands or reinvestment needs are absorbing a meaningful share of accounting earnings, reducing the cash available for debt reduction, investment, or shareholder returns.
Sartorius News
0NIR FAQ
What was Sartorius’s price range in the past 12 months?
What is Sartorius’s market cap?
When is Sartorius’s upcoming earnings report date?
How were Sartorius’s earnings last quarter?
Is Sartorius overvalued?
Does Sartorius pay dividends?
What is Sartorius’s EPS estimate?
How many shares outstanding does Sartorius have?
What happened to Sartorius’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sartorius?
What is the TipRanks Smart Score and how is it calculated?
Sartorius Stock Smart Score
Company Description
Sartorius
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include sophisticated biosensors and detection systems, live-cell analysis platforms, and a wide array of cell culture media and reagents. Sartorius also manufactures various bioreactors, ranging from benchtop to large-scale single-use and stainless steel systems, along with their associated software applications. Its extensive filtration product line encompasses membranes, specialized filters, and diverse devices for ultrafiltration, sterile filtration, and sample preparation. Furthermore, Sartorius provides process chromatography and fluid management solutions, industrial microbiology systems, water purification units, and essential lab equipment such as weighing, pipetting, and centrifugation systems. Beyond products, the company delivers critical services including bioprocess development, protein expression, and validation. Serving sectors like life science research, biopharmaceutical manufacturing, and quality control, Sartorius was established in 1870 and is headquartered in Göttingen, Germany.
- Sector
- General
- Industry
- Medical - Instruments & Supplies
- CEO
- Michael Grosse
- Employees
- 14,279
- Website
- www.sartorius.com
- Address
- Otto-Brenner-Strasse 20, Göttingen, NI, 37079, DE
Sartorius (0NIR) Earnings & Revenues
0NIR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 11 | 0 | 1 |








